```
XX
PD   24-JUN-2004.
XX
PF   05-DEC-2003; 2003WO-GB005323.
XX
PR   06-DEC-2002; 2002US-0431620P.
XX
PA   (SIGE-) SINGAPORE GEN HOSPITAL PTE LTD.
PA   (DENI/) DENISON C M.
XX
PI   Xiao Z;
XX
DR   WPI; 2004-468811/44.
DR   P-PSDB; ADQ16419.
XX
PT   New peptides that interact with myelin proteins Nogo, TNR and MAG, useful
PT   in preparing a composition for treating CNS damage, spinal cord injury or
PT   stroke.
XX
PS   Disclosure; SEQ ID NO 16; 81pp; English.
XX
CC   The present sequence encodes Nogo-66 domain b. The specification
CC   describes peptides which interact with the myelin proteins Nogo
CC   (specifically the Nogo-66 domain), the extracellular matrix glycoprotein
CC   tenascin-R (TN-R) (specifically TN-R epidermal growth factor like (TNR-
CC   EGFL)) and myelin-associated glycoprotein (MAG). These proteins have
CC   neural growth inhibitory activity. The peptide is isolated from a 7-mer
CC   phage display library exposed to a plate coated with the target protein.
CC   Peptides of the invention are useful in preparing a composition for
CC   treating central nervous system (CNS) damage, spinal cord injury or
CC   stroke. The peptides may also be used in vaccines against myelin
CC   antigens. The vaccine is based on the specific inhibitory portions of
CC   major myelin proteins, instead of the whole protein.
XX
SQ   Sequence 198 BP; 56 A; 36 C; 49 G; 57 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 25;  DB 12;  Length 198;
  Best Local Similarity   72.0%;  Pred. No. 0.079;
  Matches   18;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CUGGAUAGCUUGGAUCACACCCUUG 25
              |:|||:|||::|||:|||||||::|
Db         33 CTGGATAGCTTGGATCACACCCTTG 9


RESULT 10
ADR13967/c
ID   ADR13967 standard; cDNA; 198 BP.
XX
AC   ADR13967;
XX
DT   23-SEP-2004  (first entry)
XX
DE   Human NOGO-66 cDNA.
XX
KW   ss; gene; human; myelin-associated glycoprotein; MAG; neural growth;
KW   neural regeneration; apoptosis; amylotrophic lateral sclerosis;
KW   Alzheimer's disease; Parkinson's disease; Huntington's disease;
KW   multiple sclerosis; Creutzfeldt-Jacob disease; kuru;
KW   multiple system atrophy; Lou Gehrig's disease;
KW   progressive supranuclear palsy.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             1. .198
FT                   /*tag=  a
FT                   /partial
FT                   /product= "NOGO-66"
FT                   /note= "No start and stop codons given"
XX
PN   US2004121341-A1.
XX
PD   24-JUN-2004.
XX
PF   20-DEC-2002; 2002US-00327213.
XX
PR   20-DEC-2002; 2002US-00327213.
XX
PA   (FILB/) FILBIN M T.
PA   (DOME/) DOMENICONI M.
PA   (CAOZ/) CAO Z.
XX
PI   Filbin MT,  Domeniconi M,  Cao Z;
XX
DR   WPI; 2004-479666/45.
DR   P-PSDB; ADR13968.
XX
PT   New myelin-associated glycoprotein (MAG) derivative comprises a mutation
PT   in or flanking MAG Ig-like domain 5 (Igd5), excluding the MAG derivative
PT   MAG (d1-3)-Fc, useful promoting neural growth and regeneration.
XX
PS   Disclosure; SEQ ID NO 10; 81pp; English.
XX
CC   The invention relates to a myelin-associated glycoprotein (MAG)
CC   derivative comprising a mutation in or flanking MAG Ig-like domain 5
CC   (Igd5), excluding the MAG derivative MAG (d1-3)-Fc, where the mutation
CC   reduces or eliminates the ability of the derivative to regulate neurite
CC   outgrowth as compared to endogenous or soluble MAG without eliminating
CC   binding to neuronal surfaces. The inhibitors of MAG are useful for
CC   promoting neural growth and regeneration. They are also useful for
CC   treating neural degeneration associated with injuries, disorders, or
CC   diseases. The disorder, disease, or condition is associated with
CC   apoptosis or results from a demyelinating disease and includes
CC   amylotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease,
CC   Huntington's disease, multiple sclerosis, Creutzfeldt-Jacob disease,
CC   kuru, multiple system atrophy, amylotrophic lateral sclerosis (Lou
CC   Gehrig's disease), or progressive supranuclear palsy. The present
CC   sequence represents the human NOGO-66 cDNA.
XX
SQ   Sequence 198 BP; 56 A; 36 C; 49 G; 57 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 25;  DB 12;  Length 198;
  Best Local Similarity   72.0%;  Pred. No. 0.079;
  Matches   18;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CUGGAUAGCUUGGAUCACACCCUUG 25
              |:|||:|||::|||:|||||||::|
Db         33 CTGGATAGCTTGGATCACACCCTTG 9


RESULT 11
AAV23697/c
ID   AAV23697 standard; cDNA; 261 BP.
XX
AC   AAV23697;
XX
DT   24-JUL-1998  (first entry)
XX
DE   Human NSPLP protein coding sequence fragment.
XX
KW   NSPLP; neuroendocrine-specific protein-like protein; human; gene therapy;
KW   neurodegenerative disease; amyotrophic lateral sclerosis; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO9806841-A2.
XX
PD   19-FEB-1998.
XX
PF   24-JUL-1997;   97WO-US013469.
XX
PR   12-AUG-1996;   96US-00700607.
XX
PA   (INCY-) INCYTE PHARM INC.
XX
```

PI Bandman O, Au-Young J, Goli SK, Hillman J;
XX
DR WPI; 1998-159533/14.
XX
PT Human neuro-endocrine-specific protein-like proteins - useful for
PT diagnosis, monitoring and treatment of cancer and neuro-degenerative
PT disease.
XX
PS Disclosure; Page 45; 73pp; English.
XX
CC This sequence encodes a human neuroendocrine-specific protein-like
CC protein (NSPLP) of the invention. Recombinant cells transformed with the
CC DNA are used to express the NSPLP proteins, which are used to treat
CC cancer and neurodegenerative diseases such as amyotrophic lateral
CC sclerosis. Also antisense nucleic acids and antagonists of NSPLP can be
CC used to inhibit activity of the NSPLP proteins. Antibodies specific for
CC NSPLP are used for diagnosis and monitoring treatment of diseases
CC associated with NSPLP expression, in usual immunoassays, and to isolate
CC NSPLP from natural sources. The NSPLP proteins, or their fragments can
CC also be used in drug screening to identify NSPLP antagonists. The nucleic
CC acid can be used diagnostically and for monitoring treatment (in
CC hybridisation or amplification assays); to isolate closely related
CC sequences; in gene therapy for both sense and antisense applications
CC (including use of ribozymes) and for mapping the natural genomic sequence
XX
SQ Sequence 261 BP; 62 A; 59 C; 56 G; 67 T; 0 U; 17 Other;

Query Match 100.0%; Score 25; DB 2; Length 261;
Best Local Similarity 72.0%; Pred. No. 0.082;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGGAUAGCUUGGAUCACACCCUUG 25
|:|||:|||::|||:|||||||::|
Db 124 CTGGATAGCTTGGATCACACCCTTG 100

RESULT 12
AAX41193/c
ID AAX41193 standard; cDNA; 404 BP.
XX
AC AAX41193;
XX
DT 17-JUN-1999 (first entry)
XX
DE Human secreted protein 5' EST SEQ ID NO:137.
XX
KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition; ds.
XX
OS Homo sapiens.
XX
PN WO9906548-A2.
XX
PD 11-FEB-1999.
XX
PF 31-JUL-1998; 98WO-IB001222.
XX
PR 01-AUG-1997; 97US-00905135.
XX
PA (GEST) GENSET.
XX
PI Dumas Milne Edwards J, Duclert A, Lacroix B;
XX
DR WPI; 1999-153778/13.
DR P-PSDB; AAY12360.
XX
PT New nucleic acids encoding human secreted proteins - obtained from cDNA
PT libraries prepared from e.g. liver, ovary, brain, prostate, kidney, lung,
PT umbilical cord, placenta and colon tissue.
XX
PS Claim 1; Page 319; 824pp; English.
XX
CC AAX41094 to AAX41347 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins, and encode the proteins given in AAY12261 to
CC AAY12514, respectively. The proteins given represent the signal peptide
CC and an N-terminal fragment of a secreted protein. The nucleic acid
CC sequences can be used for producing secreted human gene products. They
CC can also be used to develop products for diagnosis and therapy. The
CC proteins obtained may have cytokine activity, cell
CC proliferation/differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductive hormone
CC regulating activity, chemotactic/ chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptide can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell
XX
SQ Sequence 404 BP; 110 A; 75 C; 108 G; 111 T; 0 U; 0 Other;

Query Match 100.0%; Score 25; DB 2; Length 404;
Best Local Similarity 72.0%; Pred. No. 0.088;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGGAUAGCUUGGAUCACACCCUUG 25
|:|||:|||::|||:|||||||::|
Db 347 CTGGATAGCTTGGATCACACCCTTG 323

RESULT 13
AAF90323/c
ID AAF90323 standard; cDNA; 600 BP.
XX
AC AAF90323;
XX
DT 23-JUL-2001 (first entry)
XX
DE Human NOGO-C cDNA.
XX
KW NOGO-C; human; chromosome 2p21; neuropathy; spinal injury; brain injury;
KW stroke; neuronal degeneration; Alzheimer's disease; Parkinson's disease;
KW neuromuscular disorder; psychiatric disorder; developmental disorder;
KW neuroprotective; nootropic; neuroleptic; antiparkinsonian;
KW cerebroprotective; neuroleptic; diagnosis; therapy; ss.
XX
OS Homo sapiens.
XX
PN WO200136631-A1.
XX
PD 25-MAY-2001.
XX
PF 14-NOV-2000; 2000WO-GB004345.
XX
PR 15-NOV-1999; 99GB-00026995.
PR 24-JAN-2000; 2000GB-00001550.
XX
PA (SMIK) SMITHKLINE BEECHAM PLC.
XX
PI Michalovich D, Prinjha R;
XX
DR WPI; 2001-343822/36.
DR P-PSDB; AAB82348.
XX
PT New polypeptide designated NOGO-C is a splice variant of the human NOGO
PT gene and may be useful in the treatment of neural disorders including
PT Alzheimer's and Parkinson's diseases.
XX
PS Claim 1; Page 25; 25pp; English.
XX
CC The present sequence is that of cDNA encoding human NOGO-C (see

CC AAB82348). NOGO-C is a novel splice variant of the human NOGO gene on
CC chromosome 2p21. 2 Other splice variants, NOGO-A and NOGO-B, have
CC previously been identified. The invention provides NOGO-C polypeptides
CC and polynucleotides, and methods for producing such polypeptides by
CC recombinant techniques. Also disclosed are methods for utilising NOGO-C
CC polypeptides and polynucleotides in the treatment of diseases including
CC neuropathies, spinal injury, brain injury, stroke, neuronal degeneration,
CC for example Alzheimer's disease and Parkinson's disease, neuromuscular
CC disorders, psychiatric disorders and developmental disorders. Also
CC provided are methods for identifying agonists and agonists for use in
CC treating conditions associated with NOGO-C imbalance, and diagnostic
CC assays for detecting diseases associated with inappropriate NOGO-C
CC activity or levels
XX
SQ Sequence 600 BP; 161 A; 113 C; 144 G; 182 T; 0 U; 0 Other;

Query Match 100.0%; Score 25; DB 4; Length 600;
Best Local Similarity 72.0%; Pred. No. 0.093;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGGAUAGCUUGGAUCACACCCUUG 25
|:|||:|||::|||:|||||||::|
Db 216 CTGGATAGCTTGGATCACACCCTTG 192

RESULT 14
ABN96987/c
ID ABN96987 standard; DNA; 639 BP.
XX
AC ABN96987;
XX
DT 13-AUG-2002 (first entry)
XX
DE Gene #3485 used to diagnose liver cancer.
XX
KW Gene; liver cancer; ds; hepatocellular carcinoma; hepatotropic;
KW metastatic liver tumour; cytostatic; expression profile; disease state;
KW disease progression; drug toxicity; drug efficacy; drug metabolism.
XX
OS Homo sapiens.
XX
PN WO200229103-A2.
XX
PD 11-APR-2002.
XX
PF 02-OCT-2001; 2001WO-US030589.
XX
PR 02-OCT-2000; 2000US-0237054P.
XX
PA (GENE-) GENE LOGIC INC.
XX
PI Horne D, Alvares C, Peres-Da-Silva S, Vockley JG;
XX
DR WPI; 2002-426119/45.
XX
PT Diagnosing and detecting the progression of liver cancer, hepatocellular
PT carcinoma or metastatic liver tumor in a patient, involves detecting the
PT level of expression of two or more genes in a liver tissue sample.
XX
PS Claim 1; SEQ ID NO 3485; 298pp; English.
XX
CC The invention relates to a novel method for diagnosing and detecting the
CC progression of liver cancer, hepatocellular carcinoma or metastatic liver
CC tumour in a patient, and differentiating metastatic liver cancer from
CC hepatocellular carcinoma in a patient, involving detecting the level of
CC expression of two or more genes represented in ABN93503-ABN97455 in a
CC tissue sample. The method of the invention has hepatotropic, and
CC cytostatic activity. The method is useful for diagnosing and detecting
CC the progression of liver cancer, hepatocellular carcinoma and metastatic
CC liver carcinoma in a patient. The method is useful for identifying
CC expression profiles which serve as useful diagnostic markers as well as
CC markers that can be used to monitor disease states, disease progression,
CC drug toxicity, drug efficacy and drug metabolism. Note: The sequence data
CC for this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 639 BP; 138 A; 114 C; 149 G; 147 T; 0 U; 91 Other;

Query Match 100.0%; Score 25; DB 6; Length 639;
Best Local Similarity 72.0%; Pred. No. 0.094;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGGAUAGCUUGGAUCACACCCUUG 25
|:|||:|||::|||:|||||||::|
Db 415 CTGGATAGCTTGGATCACACCCTTG 391

RESULT 15
ABL89601/c
ID ABL89601 standard; cDNA; 668 BP.
XX
AC ABL89601;
XX
DT 24-MAY-2002 (first entry)
XX
DE Human polynucleotide SEQ ID NO 163.
XX
KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200190304-A2.
XX
PD 29-NOV-2001.
XX
PF 18-MAY-2001; 2001WO-US016450.
XX
PR 19-MAY-2000; 2000US-0205515P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Birse CE, Rosen CA;
XX
DR WPI; 2002-122018/16.
DR P-PSDB; ABB89192.
XX
PT Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
PT prevention of neural, immune system, muscular, reproductive,
PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
PT disorders.
XX
PS Claim 4; SEQ ID NO 163; 2081pp + Sequence Listing; English.
XX
CC The invention relates to novel genes (ABL89449-ABL90853) and proteins
CC (ABB89040-ABB90444) useful for preventing, treating or ameliorating
CC medical conditions e.g. by protein or gene therapy. The genes are
CC isolated from a range of human tissues disclosed in the specification.
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC infectious diseases such as viral, bacterial, fungal and parasitic
CC infections. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX